Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: Focusing on CYP2A6

Shizuo Narimatsu, Ryoko Nakanishi, Nobumitsu Hanioka, Keita Saito, Hiroyuki Kataoka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Perfluorooctane sulfonate (PFOS) is a chemically stable compound extensively used as oil and water repellent, surface active agents in our daily life. Accumulative research evidence gradually appears the toxicity of PFOS against mammals, but the whole figure remains to be elucidated. The present study was conducted to know the effects of PFOS on human hepatic drug metabolizing-type cytochrome P450 (CYP) isoenzymes such as CYP1A2 (7-ethoxyresorufin as a substrate), CYP2A6 (coumarin), CYP2B6 (7-ethoxy-4-trifluoromethylcoumarin), CYP2C8 (paclitaxel), CYP2C9 (diclofenac), CYP2C19 (S-mephenytoin), CYP2D6 (bufuralol), CYP2E1 (chlorzoxazone) and CYP3A4 (testosterone) in human livers employing their typical substrates. Although all of the oxidation reactions tested were more or less inhibited by PFOS, diclofenac 4′-hydroxylation mediated mainly by CYP2C9 was most strongly inhibited (K i value of 40 nM), followed by paclitaxel 6α-hydroxylation mediated mainly by CYP2C8 (K i value of 4 μM). The substrate oxidation reactions catalyzed by CYP2A6, CYP2B6, CYP2C19 and CYP3A4 were moderately (K i values of 35 to 45 μM), and those by CYP1A2, CYP2D6 and CYP2E1 were weakly inhibited by PFOS (K i values of 190-300 μM). The inhibition by PFOS for coumarin 7-hydroxylation mainly catalyzed by human liver microsomal CYP2A6 as well as by the recombinant enzyme was found to be enhanced by the preincubation of PFOS with human liver microsomes and NADPH as compared to the case without preincubation. The inhibition of the human liver microsomal cumarin 7-hydroxylation was PFOS concentration-dependent, and exhibited pseudo-first-order kinetics with respect to preincubation time, yielding K inact and K I values of 0.06 min -1 and 23 μM, respectively. These results suggest that the metabolism of medicines which are substrates for CYP2C9 may be altered by PFOS in human bodies, and that PFOS is a mechanism-based inhibitor of CYP2A6.

Original languageEnglish
Pages (from-to)120-126
Number of pages7
JournalChemico-Biological Interactions
Volume194
Issue number2-3
DOIs
Publication statusPublished - Nov 15 2011

Fingerprint

Cytochrome P-450 Enzyme System
Isoenzymes
Liver
Hydroxylation
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2E1
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6
Diclofenac
Substrates
Paclitaxel
Chlorzoxazone
Mephenytoin
perfluorooctane sulfonic acid
Oxidation
Mammals
Liver Microsomes
NADP
Human Body
Metabolism

Keywords

  • CYP2A6
  • CYP2C9
  • Human liver microsomes
  • Mechanism-based inactivation
  • PFOS
  • Recombinant enzyme

ASJC Scopus subject areas

  • Toxicology

Cite this

Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes : Focusing on CYP2A6. / Narimatsu, Shizuo; Nakanishi, Ryoko; Hanioka, Nobumitsu; Saito, Keita; Kataoka, Hiroyuki.

In: Chemico-Biological Interactions, Vol. 194, No. 2-3, 15.11.2011, p. 120-126.

Research output: Contribution to journalArticle

Narimatsu, Shizuo ; Nakanishi, Ryoko ; Hanioka, Nobumitsu ; Saito, Keita ; Kataoka, Hiroyuki. / Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes : Focusing on CYP2A6. In: Chemico-Biological Interactions. 2011 ; Vol. 194, No. 2-3. pp. 120-126.
@article{53a09256bd4e4507a3ca2297d3335bb8,
title = "Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: Focusing on CYP2A6",
abstract = "Perfluorooctane sulfonate (PFOS) is a chemically stable compound extensively used as oil and water repellent, surface active agents in our daily life. Accumulative research evidence gradually appears the toxicity of PFOS against mammals, but the whole figure remains to be elucidated. The present study was conducted to know the effects of PFOS on human hepatic drug metabolizing-type cytochrome P450 (CYP) isoenzymes such as CYP1A2 (7-ethoxyresorufin as a substrate), CYP2A6 (coumarin), CYP2B6 (7-ethoxy-4-trifluoromethylcoumarin), CYP2C8 (paclitaxel), CYP2C9 (diclofenac), CYP2C19 (S-mephenytoin), CYP2D6 (bufuralol), CYP2E1 (chlorzoxazone) and CYP3A4 (testosterone) in human livers employing their typical substrates. Although all of the oxidation reactions tested were more or less inhibited by PFOS, diclofenac 4′-hydroxylation mediated mainly by CYP2C9 was most strongly inhibited (K i value of 40 nM), followed by paclitaxel 6α-hydroxylation mediated mainly by CYP2C8 (K i value of 4 μM). The substrate oxidation reactions catalyzed by CYP2A6, CYP2B6, CYP2C19 and CYP3A4 were moderately (K i values of 35 to 45 μM), and those by CYP1A2, CYP2D6 and CYP2E1 were weakly inhibited by PFOS (K i values of 190-300 μM). The inhibition by PFOS for coumarin 7-hydroxylation mainly catalyzed by human liver microsomal CYP2A6 as well as by the recombinant enzyme was found to be enhanced by the preincubation of PFOS with human liver microsomes and NADPH as compared to the case without preincubation. The inhibition of the human liver microsomal cumarin 7-hydroxylation was PFOS concentration-dependent, and exhibited pseudo-first-order kinetics with respect to preincubation time, yielding K inact and K I values of 0.06 min -1 and 23 μM, respectively. These results suggest that the metabolism of medicines which are substrates for CYP2C9 may be altered by PFOS in human bodies, and that PFOS is a mechanism-based inhibitor of CYP2A6.",
keywords = "CYP2A6, CYP2C9, Human liver microsomes, Mechanism-based inactivation, PFOS, Recombinant enzyme",
author = "Shizuo Narimatsu and Ryoko Nakanishi and Nobumitsu Hanioka and Keita Saito and Hiroyuki Kataoka",
year = "2011",
month = "11",
day = "15",
doi = "10.1016/j.cbi.2011.09.002",
language = "English",
volume = "194",
pages = "120--126",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes

T2 - Focusing on CYP2A6

AU - Narimatsu, Shizuo

AU - Nakanishi, Ryoko

AU - Hanioka, Nobumitsu

AU - Saito, Keita

AU - Kataoka, Hiroyuki

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Perfluorooctane sulfonate (PFOS) is a chemically stable compound extensively used as oil and water repellent, surface active agents in our daily life. Accumulative research evidence gradually appears the toxicity of PFOS against mammals, but the whole figure remains to be elucidated. The present study was conducted to know the effects of PFOS on human hepatic drug metabolizing-type cytochrome P450 (CYP) isoenzymes such as CYP1A2 (7-ethoxyresorufin as a substrate), CYP2A6 (coumarin), CYP2B6 (7-ethoxy-4-trifluoromethylcoumarin), CYP2C8 (paclitaxel), CYP2C9 (diclofenac), CYP2C19 (S-mephenytoin), CYP2D6 (bufuralol), CYP2E1 (chlorzoxazone) and CYP3A4 (testosterone) in human livers employing their typical substrates. Although all of the oxidation reactions tested were more or less inhibited by PFOS, diclofenac 4′-hydroxylation mediated mainly by CYP2C9 was most strongly inhibited (K i value of 40 nM), followed by paclitaxel 6α-hydroxylation mediated mainly by CYP2C8 (K i value of 4 μM). The substrate oxidation reactions catalyzed by CYP2A6, CYP2B6, CYP2C19 and CYP3A4 were moderately (K i values of 35 to 45 μM), and those by CYP1A2, CYP2D6 and CYP2E1 were weakly inhibited by PFOS (K i values of 190-300 μM). The inhibition by PFOS for coumarin 7-hydroxylation mainly catalyzed by human liver microsomal CYP2A6 as well as by the recombinant enzyme was found to be enhanced by the preincubation of PFOS with human liver microsomes and NADPH as compared to the case without preincubation. The inhibition of the human liver microsomal cumarin 7-hydroxylation was PFOS concentration-dependent, and exhibited pseudo-first-order kinetics with respect to preincubation time, yielding K inact and K I values of 0.06 min -1 and 23 μM, respectively. These results suggest that the metabolism of medicines which are substrates for CYP2C9 may be altered by PFOS in human bodies, and that PFOS is a mechanism-based inhibitor of CYP2A6.

AB - Perfluorooctane sulfonate (PFOS) is a chemically stable compound extensively used as oil and water repellent, surface active agents in our daily life. Accumulative research evidence gradually appears the toxicity of PFOS against mammals, but the whole figure remains to be elucidated. The present study was conducted to know the effects of PFOS on human hepatic drug metabolizing-type cytochrome P450 (CYP) isoenzymes such as CYP1A2 (7-ethoxyresorufin as a substrate), CYP2A6 (coumarin), CYP2B6 (7-ethoxy-4-trifluoromethylcoumarin), CYP2C8 (paclitaxel), CYP2C9 (diclofenac), CYP2C19 (S-mephenytoin), CYP2D6 (bufuralol), CYP2E1 (chlorzoxazone) and CYP3A4 (testosterone) in human livers employing their typical substrates. Although all of the oxidation reactions tested were more or less inhibited by PFOS, diclofenac 4′-hydroxylation mediated mainly by CYP2C9 was most strongly inhibited (K i value of 40 nM), followed by paclitaxel 6α-hydroxylation mediated mainly by CYP2C8 (K i value of 4 μM). The substrate oxidation reactions catalyzed by CYP2A6, CYP2B6, CYP2C19 and CYP3A4 were moderately (K i values of 35 to 45 μM), and those by CYP1A2, CYP2D6 and CYP2E1 were weakly inhibited by PFOS (K i values of 190-300 μM). The inhibition by PFOS for coumarin 7-hydroxylation mainly catalyzed by human liver microsomal CYP2A6 as well as by the recombinant enzyme was found to be enhanced by the preincubation of PFOS with human liver microsomes and NADPH as compared to the case without preincubation. The inhibition of the human liver microsomal cumarin 7-hydroxylation was PFOS concentration-dependent, and exhibited pseudo-first-order kinetics with respect to preincubation time, yielding K inact and K I values of 0.06 min -1 and 23 μM, respectively. These results suggest that the metabolism of medicines which are substrates for CYP2C9 may be altered by PFOS in human bodies, and that PFOS is a mechanism-based inhibitor of CYP2A6.

KW - CYP2A6

KW - CYP2C9

KW - Human liver microsomes

KW - Mechanism-based inactivation

KW - PFOS

KW - Recombinant enzyme

UR - http://www.scopus.com/inward/record.url?scp=80054058525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054058525&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2011.09.002

DO - 10.1016/j.cbi.2011.09.002

M3 - Article

C2 - 21964418

AN - SCOPUS:80054058525

VL - 194

SP - 120

EP - 126

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 2-3

ER -